A Randomized, Controlled, Partially Blinded Phase llb Dose-Finding Trial of TMC125M, in HIV-1 Infected Subjects with Documented Geontypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations.

Grants and Contracts Details

StatusFinished
Effective start/end date6/22/04 → 6/30/11

Funding

  • Tibotec Pharmaceuticals Ltd: $43,994.00